In-Vitro diagnostic backgroundMULDIA is focused on three targets:
Advanced IVD Molecular Diagnosis:
Determination of multiple biomarkers (Panel of Biomarkers or multiplexing) to help diagnose, follow progression, determine risk factors and prognosis of the disease.
Point of Care (PoC) testing:
In situ diagnostic which do not require specialized or qualified personnel and allow a significant reduction in the cost of diagnosis and time.
High Throughput Screening:
Capacity for measuring as many biomarkers as possible with the ability to measure in the shortest possible time
In Spain, there are no commercially available equipment for in vitro analysis and very few in Europe as a whole, until now. MULDIA aims to revolutionise the world of diagnostics with an innovative technological platform allows for the detection of several biomarkers efficiently at the same time at a low cost. This will allow fatal diseases such as cancer, infections, autoimmune and cardiovascular diseases to be detected much earlier than with traditional diagnostic tools.
MulDia has developed a unique, extremely versatile, accurate and reliable In-Vitro detection system capable of detecting different biomolecules such as small molecules, proteins, antibodies, or oligonucleotides, among others. MULDIA can detect these specimens from a wide range of sources from blood to urine to tears and even wastewater all within a small volume of the sample.
MULDIA's detection system is based on a patented technology called optical interferometry, which consists of a network of sensors that emit a certain signal when molecules are present in the sample. MULDIA also has a patented novel detection system that allows the targeted biomolecules to be detected quickly even when they are in small quantities. Moreover, MULDIA technology significantly reduces the amount of chemical reagent needed in comparison with the competitors.
MulDia has developed a unique, extremely versatile, accurate and reliable In-Vitro detection system capable of detecting different biomolecules such as small molecules, proteins, antibodies, or oligonucleotides, among others. MULDIA can detect these specimens from a wide range of sources from blood to urine to tears and even wastewater all within a small volume of the sample.
MULDIA's detection system is based on a patented technology called optical interferometry, which consists of a network of sensors that emit a certain signal when molecules are present in the sample. MULDIA also has a patented novel detection system that allows the targeted biomolecules to be detected quickly even when they are in small quantities. Moreover, MULDIA technology significantly reduces the amount of chemical reagent needed in comparison with the competitors.
Accurate and reliable measurement
Able to detect biomarkers when they are present in the sample without generating false positives with results comparable to those of competing systems.
Versatility of use and high screening capacity
Can screen multiple biomarkers, samples and/or patients simultaneously (up to 1,500 measurements in a single diagnostic kit).
Efficiency and Speed
Obtains results in a short time (10 minutes + incubation time) and with a relatively low sample volume (1 microlitre per well, i.e. one millionth of 1 litre).
Cost effective
It requires few chemical reagents compared to other options on the market. Only nanograms of reagent are needed for each well.
Small size
The device that fits into any workspace, making it a «Point of Care» device that can be used in any medical practice.
Ease of use
It does not require the presence of qualified personnel for its use.
MULDIA TECHNOLOGYMULDIA is based on optical technology for measuring multiple molecules in real biological samples
Blood/Serum
Urine
Saliva
Tears
Cells
Water
Wastewater
These samples have many components plus the target biomolecules in a limited volume of sample.
The MULDIA diagnostic systems can determine a broad range of biomarkers, ranging form small molecules, proteins, antibodies, or oligonucleotides among others.
MULDIA is designed to be adapted and customised for use in different applications
The device has been used in several centres across multiple countries to validate the effectiveness of the technology. In each of the centres, it has been used for different applications, including the following:
Food allergy diagnosis:
Detection of serum IgEs (the results were compared with those obtained using the main test used for the diagnosis of food allergies, demonstrating that both results were comparable).
Alzheimer disease biomarker detection:
Quantify the concentration of Tau protein in serum (the results obtained were shown to be equivalent to those of other diagnostic techniques (e.g. ELISA)).
SARS-CoV-2 detection in wastewater:
Simultaneous detection of 2 virus molecules (S1 protein and nucleocapsid), with very satisfactory results and a lower complexity and cost than PCR.
COVID-19 biomarkers detection in serum and saliva:
Multiple biomarkers such as antibodies (IgG, IgM, IgA) and inflammatory molecules (C-Reactive Protein and Ferritin) were measured to aid in the diagnosis and monitoring of the disease.
Lactoferrin detection in tears:
Useful for the diagnosis of ophthalmic pathologies such as dry eye, keratoconus or papillary conjunctivitis, as these patients usually have increased or decreased levels of lactoferrin. The results obtained with MULDIA were comparable to those obtained with other diagnostic techniques (e.g. ELISA).
The device has been used in several centres across multiple countries to validate the effectiveness of the technology. In each of the centres, it has been used for different applications, including the following:
Food allergy diagnosis:
Detection of serum IgEs (the results were compared with those obtained using the main test used for the diagnosis of food allergies, demonstrating that both results were comparable).
Alzheimer disease biomarker detection:
Quantify the concentration of Tau protein in serum (the results obtained were shown to be equivalent to those of other diagnostic techniques (e.g. ELISA)).
SARS-CoV-2 detection in wastewater:
Simultaneous detection of 2 virus molecules (S1 protein and nucleocapsid), with very satisfactory results and a lower complexity and cost than PCR.
COVID-19 biomarkers detection in serum and saliva:
Multiple biomarkers such as antibodies (IgG, IgM, IgA) and inflammatory molecules (C-Reactive Protein and Ferritin) were measured to aid in the diagnosis and monitoring of the disease.
Lactoferrin detection in tears:
Useful for the diagnosis of ophthalmic pathologies such as dry eye, keratoconus or papillary conjunctivitis, as these patients usually have increased or decreased levels of lactoferrin. The results obtained with MULDIA were comparable to those obtained with other diagnostic techniques (e.g. ELISA).
Multiplex Molecular Diagnostics, S.L. is a startup company belonging to the Brill group of companies. Created in 2022 is focused on the development, registration, industrialization and commercialization of Advanced IVD Molecular Diagnostics systems.
Copyright 2022, Multiplex Molecular Diagnostic, S.L.. All rights reserved. Privacy Policy, Legal Notice, Cookies Policy.